REFERENCES
1. Spencer MR, Miniño AM, Warner M. Drug Overdose Deaths in the United
States, 2001-2021. NCHS Data Brief . Dec 2022;(457):1-8.
2. Ciccarone D. The triple wave epidemic: Supply and demand drivers of
the US opioid overdose crisis. Int J Drug Policy . Sep
2019;71:183-188. doi:10.1016/j.drugpo.2019.01.010
3. Kolodny A, Courtwright DT, Hwang CS, et al. The prescription opioid
and heroin crisis: a public health approach to an epidemic of addiction.Annu Rev Public Health . Mar 18 2015;36:559-74.
doi:10.1146/annurev-publhealth-031914-122957
4. Vital signs: overdoses of prescription opioid pain relievers and
other drugs among women–United States, 1999-2010. MMWR Morb
Mortal Wkly Rep . Jul 5 2013;62(26):537-42.
5. Barry DT, Beitel M, Joshi D, Schottenfeld RS. Pain and
substance-related pain-reduction behaviors among opioid dependent
individuals seeking methadone maintenance treatment. Am J Addict .
Mar-Apr 2009;18(2):117-21. doi:10.1080/10550490902772470
6. Mun CJ, Beitel M, Oberleitner L, et al. Pain catastrophizing and pain
acceptance are associated with pain severity and interference among
methadone-maintained patients. J Clin Psychol . Dec
2019;75(12):2233-2247. doi:10.1002/jclp.22842
7. Oliveira D, Fontenele R, Weleff J, Sofuoglu M, De Aquino JP.
Developing non-opioid therapeutics to alleviate pain among persons with
opioid use disorder: a review of the human evidence. International
Review of Psychiatry . 2023:1-20. doi:10.1080/09540261.2023.2229430
8. Fuehrlein BS, Ross DA. Opioid Use Disorder: A Desperate Need for
Novel Treatments. Biol Psychiatry . Apr 1 2017;81(7):e43-e45.
doi:10.1016/j.biopsych.2017.01.014
9. De Aquino JP, Parida S, Avila-Quintero VJ, et al. Opioid-induced
analgesia among persons with opioid use disorder receiving methadone or
buprenorphine: A systematic review of experimental pain studies.Drug Alcohol Depend . Nov 1 2021;228:109097.
doi:10.1016/j.drugalcdep.2021.109097
10. Nichols DE. Psychedelics. Pharmacol Rev . Apr
2016;68(2):264-355. doi:10.1124/pr.115.011478
11. Savage C, McCabe OL. Residential psychedelic (LSD) therapy for the
narcotic addict. A controlled study. Arch Gen Psychiatry . Jun
1973;28(6):808-14. doi:10.1001/archpsyc.1973.01750360040005
12. Ludwig AM, Levine J. A CONTROLLED COMPARISON OF FIVE BRIEF TREATMENT
TECHNIQUES EMPLOYING LSD, HYPNOSIS, AND PSYCHOTHERAPY. Am J
Psychother . Jul 1965;19:417-35.
doi:10.1176/appi.psychotherapy.1965.19.3.417
13. Kast EC, Collins VJ. STUDY OF LYSERGIC ACID DIETHYLAMIDE AS AN
ANALGESIC AGENT. Anesth Analg . May-Jun 1964;43:285-91.
14. Bogenschutz MP, Ross S, Bhatt S, et al. Percentage of Heavy Drinking
Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the
Treatment of Adult Patients With Alcohol Use Disorder: A Randomized
Clinical Trial. JAMA Psychiatry . Oct 1 2022;79(10):953-962.
doi:10.1001/jamapsychiatry.2022.2096
15. Johnson MW, Garcia-Romeu A, Griffiths RR. Long-term follow-up of
psilocybin-facilitated smoking cessation. Am J Drug Alcohol
Abuse . Jan 2017;43(1):55-60. doi:10.3109/00952990.2016.1170135
16. Mosca A, Chiappini S, Miuli A, et al. Ibogaine/Noribogaine in the
Treatment of Substance Use Disorders: a Systematic Review of the Current
Literature. Curr Neuropharmacol . Oct 17
2022;doi:10.2174/1570159x21666221017085612
17. van der Meer PB, Fuentes JJ, Kaptein AA, et al. Therapeutic effect
of psilocybin in addiction: A systematic review. Front
Psychiatry . 2023;14:1134454. doi:10.3389/fpsyt.2023.1134454
18. Liester MB. A review of lysergic acid diethylamide (LSD) in the
treatment of addictions: historical perspectives and future prospects.Curr Drug Abuse Rev . 2014;7(3):146-56.
doi:10.2174/1874473708666150107120522
19. Bogenschutz MP, Johnson MW. Classic hallucinogens in the treatment
of addictions. Prog Neuropsychopharmacol Biol Psychiatry . Jan 4
2016;64:250-8. doi:10.1016/j.pnpbp.2015.03.002
20. Rodrigues LS, Rossi GN, Rocha JM, et al. Effects of ayahuasca and
its alkaloids on substance use disorders: an updated (2016-2020)
systematic review of preclinical and human studies. Eur Arch
Psychiatry Clin Neurosci . Jun 2022;272(4):541-556.
doi:10.1007/s00406-021-01267-7
21. Kelmendi B, Kaye AP, Pittenger C, Kwan AC. Psychedelics. Curr
Biol . Jan 24 2022;32(2):R63-r67. doi:10.1016/j.cub.2021.12.009
22. Nakagawasai O, Arai Y, Satoh SE, et al. Monoamine oxidase and
head-twitch response in mice. Mechanisms of alpha-methylated substrate
derivatives. Neurotoxicology . Jan 2004;25(1-2):223-32.
doi:10.1016/s0161-813x(03)00101-3
23. Silva MT, Calil HM. Screening hallucinogenic drugs: systematic study
of three behavioral tests. Psychopharmacologia . May 28
1975;42(2):163-71. doi:10.1007/bf00429548
24. Yamamoto T, Ueki S. The role of central serotonergic mechanisms on
head-twitch and backward locomotion induced by hallucinogenic drugs.Pharmacol Biochem Behav . Jan 1981;14(1):89-95.
doi:10.1016/0091-3057(81)90108-8
25. de Vos CMH, Mason NL, Kuypers KPC. Psychedelics and Neuroplasticity:
A Systematic Review Unraveling the Biological Underpinnings of
Psychedelics. Front Psychiatry . 2021;12:724606.
doi:10.3389/fpsyt.2021.724606
26. Price DD. Psychological and neural mechanisms of the affective
dimension of pain. Science . Jun 9 2000;288(5472):1769-72.
doi:10.1126/science.288.5472.1769
27. Bardin L. The complex role of serotonin and 5-HT receptors in
chronic pain. Behav Pharmacol . Sep 2011;22(5-6):390-404.
doi:10.1097/FBP.0b013e328349aae4
28. Bondy B, Spaeth M, Offenbaecher M, et al. The T102C polymorphism of
the 5-HT2A-receptor gene in fibromyalgia. Neurobiol Dis . Oct
1999;6(5):433-9. doi:10.1006/nbdi.1999.0262
29. Nicholl BI, Holliday KL, Macfarlane GJ, et al. Association of HTR2A
polymorphisms with chronic widespread pain and the extent of
musculoskeletal pain: results from two population-based cohorts.Arthritis Rheum . Mar 2011;63(3):810-8. doi:10.1002/art.30185
30. Talbot K, Madden VJ, Jones SL, Moseley GL. The sensory and affective
components of pain: are they differentially modifiable dimensions or
inseparable aspects of a unitary experience? A systematic review.Br J Anaesth . Aug 2019;123(2):e263-e272.
doi:10.1016/j.bja.2019.03.033
31. Okamoto K, Imbe H, Morikawa Y, et al. 5-HT2A receptor subtype in the
peripheral branch of sensory fibers is involved in the potentiation of
inflammatory pain in rats. Pain . Sep 2002;99(1-2):133-43.
doi:10.1016/s0304-3959(02)00070-2
32. Patel R, Dickenson AH. Modality selective roles of pro-nociceptive
spinal 5-HT(2A) and 5-HT(3) receptors in normal and neuropathic states.Neuropharmacology . Dec 2018;143:29-37.
doi:10.1016/j.neuropharm.2018.09.028
33. Liu QQ, Yao XX, Gao SH, et al. Role of 5-HT receptors in neuropathic
pain: potential therapeutic implications. Pharmacol Res . Sep
2020;159:104949. doi:10.1016/j.phrs.2020.104949
34. López-Giménez JF, González-Maeso J. Hallucinogens and Serotonin
5-HT(2A) Receptor-Mediated Signaling Pathways. Curr Top Behav
Neurosci . 2018;36:45-73. doi:10.1007/7854_2017_478
35. Haleem DJ. Serotonin-1A receptor dependent modulation of pain and
reward for improving therapy of chronic pain. Pharmacol Res . Aug
2018;134:212-219. doi:10.1016/j.phrs.2018.06.030
36. Seifert O, Baerwald C. Interaction of pain and chronic inflammation.Z Rheumatol . Apr 2021;80(3):205-213. Wechselwirkungen von Schmerz
und chronischer Entzündung. doi:10.1007/s00393-020-00951-8
37. Flanagan TW, Nichols CD. Psychedelics as anti-inflammatory agents.Int Rev Psychiatry . Aug 2018;30(4):363-375.
doi:10.1080/09540261.2018.1481827
38. Abbott FV, Hong Y, Blier P. Activation of 5-HT2A receptors
potentiates pain produced by inflammatory mediators.Neuropharmacology . Jan 1996;35(1):99-110.
doi:10.1016/0028-3908(95)00136-0
39. Puderbaugh M, Emmady PD. Neuroplasticity. StatPearls .
StatPearls Publishing
Copyright © 2023, StatPearls Publishing LLC.; 2023.
40. Shen W, Tu Y, Gollub RL, et al. Visual network alterations in brain
functional connectivity in chronic low back pain: A resting state
functional connectivity and machine learning study. Neuroimage
Clin . 2019;22:101775. doi:10.1016/j.nicl.2019.101775
41. Baliki MN, Mansour AR, Baria AT, Apkarian AV. Functional
reorganization of the default mode network across chronic pain
conditions. PLoS One . 2014;9(9):e106133.
doi:10.1371/journal.pone.0106133
42. Baliki MN, Geha PY, Apkarian AV, Chialvo DR. Beyond feeling: chronic
pain hurts the brain, disrupting the default-mode network dynamics.J Neurosci . Feb 6 2008;28(6):1398-403.
doi:10.1523/jneurosci.4123-07.2008
43. Baliki MN, Petre B, Torbey S, et al. Corticostriatal functional
connectivity predicts transition to chronic back pain. Nat
Neurosci . Jul 1 2012;15(8):1117-9. doi:10.1038/nn.3153
44. Ly C, Greb AC, Cameron LP, et al. Psychedelics Promote Structural
and Functional Neural Plasticity. Cell Rep . Jun 12
2018;23(11):3170-3182. doi:10.1016/j.celrep.2018.05.022
45. Hipólito I, Mago J, Rosas FE, Carhart-Harris R. Pattern breaking: a
complex systems approach to psychedelic medicine. Neurosci
Conscious . 2023;2023(1):niad017. doi:10.1093/nc/niad017
46. Carhart-Harris RL, Chandaria S, Erritzoe DE, et al. Canalization and
plasticity in psychopathology. Neuropharmacology . Mar 15
2023;226:109398. doi:10.1016/j.neuropharm.2022.109398
47. Gracely RH, Harte SE. Emotional/Affective Aspects of Pain. In:
Binder MD, Hirokawa N, Windhorst U, eds. Encyclopedia of
Neuroscience . Springer Berlin Heidelberg; 2009:1092-1095.
48. Kasanetz F, Acuña MA, Nevian T. Chapter 18 - Anterior cingulate
cortex, pain perception, and pathological neuronal plasticity during
chronic pain. In: Rajendram R, Patel VB, Preedy VR, Martin CR, eds.The Neurobiology, Physiology, and Psychology of Pain . Academic
Press; 2022:193-202.
49. Carhart-Harris RL, Erritzoe D, Williams T, et al. Neural correlates
of the psychedelic state as determined by fMRI studies with psilocybin.Proc Natl Acad Sci U S A . Feb 7 2012;109(6):2138-43.
doi:10.1073/pnas.1119598109
50. Barba T, Buehler S, Kettner H, et al. Effects of psilocybin versus
escitalopram on rumination and thought suppression in depression.BJPsych Open . Sep 6 2022;8(5):e163. doi:10.1192/bjo.2022.565
51. Bair MJ, Robinson RL, Katon W, Kroenke K. Depression and pain
comorbidity: a literature review. Arch Intern Med . Nov 10
2003;163(20):2433-45. doi:10.1001/archinte.163.20.2433
52. Dick BD, Rashiq S. Disruption of attention and working memory traces
in individuals with chronic pain. Anesth Analg . May
2007;104(5):1223-9, tables of contents.
doi:10.1213/01.ane.0000263280.49786.f5
53. Linton SJ, Shaw WS. Impact of psychological factors in the
experience of pain. Phys Ther . May 2011;91(5):700-11.
doi:10.2522/ptj.20100330
54. Meier ML, Stämpfli P, Vrana A, Humphreys BK, Seifritz E,
Hotz-Boendermaker S. Neural Correlates of Fear of Movement in Patients
with Chronic Low Back Pain vs. Pain-Free Individuals. Front Hum
Neurosci . 2016;10:386. doi:10.3389/fnhum.2016.00386
55. Schütze R, Rees C, Smith A, Slater H, O’Sullivan P. Metacognition,
perseverative thinking, and pain catastrophizing: A moderated-mediation
analysis. Eur J Pain . Jan 2020;24(1):223-233.
doi:10.1002/ejp.1479
56. Ziadni MS, Sturgeon JA, Darnall BD. The relationship between
negative metacognitive thoughts, pain catastrophizing and adjustment to
chronic pain. Eur J Pain . Apr 2018;22(4):756-762.
doi:10.1002/ejp.1160
57. Sweat NW, Bates LW, Hendricks PS. The Associations of Naturalistic
Classic Psychedelic Use, Mystical Experience, and Creative Problem
Solving. J Psychoactive Drugs . Nov-Dec 2016;48(5):344-350.
doi:10.1080/02791072.2016.1234090
58. Millière R, Carhart-Harris RL, Roseman L, Trautwein FM,
Berkovich-Ohana A. Psychedelics, Meditation, and Self-Consciousness.Front Psychol . 2018;9:1475. doi:10.3389/fpsyg.2018.01475
59. MacLean RR, Sofuoglu M, Brede E, Robinson C, Waters AJ. Attentional
bias in opioid users: A systematic review and meta-analysis. Drug
Alcohol Depend . Oct 1 2018;191:270-278.
doi:10.1016/j.drugalcdep.2018.07.012
60. Schoth DE, Nunes Vd Fau - Liossi C, Liossi C. Attentional bias
towards pain-related information in chronic pain; a meta-analysis of
visual-probe investigations. (1873-7811 (Electronic))
61. MacLean RR, Heapy AA, Waters AJ, et al. Integrating cognitive bias
modification for pain and opioid cues into medication for opioid use
disorder clinical care: Feasibility, acceptability, and preliminary
results. (1879-0046 (Electronic))
62. Griffiths RR, Johnson MW, Richards WA, et al. Psilocybin-occasioned
mystical-type experience in combination with meditation and other
spiritual practices produces enduring positive changes in psychological
functioning and in trait measures of prosocial attitudes and behaviors.J Psychopharmacol . Jan 2018;32(1):49-69.
doi:10.1177/0269881117731279
63. Forstmann M, Yudkin DA, Prosser AMB, Heller SM, Crockett MJ.
Transformative experience and social connectedness mediate the
mood-enhancing effects of psychedelic use in naturalistic settings.Proc Natl Acad Sci U S A . Feb 4 2020;117(5):2338-2346.
doi:10.1073/pnas.1918477117
64. Weiss B, Nygart V, Pommerencke LM, Carhart-Harris RL, Erritzoe D.
Examining Psychedelic-Induced Changes in Social Functioning and
Connectedness in a Naturalistic Online Sample Using the Five-Factor
Model of Personality. Front Psychol . 2021;12:749788.
doi:10.3389/fpsyg.2021.749788
65. Ong AD, Thoemmes F, Ratner K, Ghezzi-Kopel K, Reid MC. Positive
affect and chronic pain: a preregistered systematic review and
meta-analysis. (1872-6623 (Electronic))
66. Whelan A, Johnson MI. Lysergic acid diethylamide and psilocybin for
the management of patients with persistent pain: a potential role?Pain Manag . May 2018;8(3):217-229. doi:10.2217/pmt-2017-0068
67. Ramaekers JG, Hutten N, Mason NL, et al. A low dose of lysergic acid
diethylamide decreases pain perception in healthy volunteers. J
Psychopharmacol . Apr 2021;35(4):398-405. doi:10.1177/0269881120940937
68. Reiche S, Hermle L, Gutwinski S, Jungaberle H, Gasser P, Majić T.
Serotonergic hallucinogens in the treatment of anxiety and depression in
patients suffering from a life-threatening disease: A systematic review.Prog Neuropsychopharmacol Biol Psychiatry . Feb 2 2018;81:1-10.
doi:10.1016/j.pnpbp.2017.09.012
69. Kooijman NI, Willegers T, Reuser A, et al. Are psychedelics the
answer to chronic pain: A review of current literature. Pain
Pract . Apr 2023;23(4):447-458. doi:10.1111/papr.13203
70. Grof S, Goodman LE, Richards WA, Kurland AA. LSD-assisted
psychotherapy in patients with terminal cancer. Int
Pharmacopsychiatry . 1973;8(3):129-44. doi:10.1159/000467984
71. Kurland AA. LSD in the supportive care of the terminally ill cancer
patient. J Psychoactive Drugs . Oct-Dec 1985;17(4):279-90.
doi:10.1080/02791072.1985.10524332
72. Fuentes JJ, Fonseca F, Elices M, Farré M, Torrens M. Therapeutic Use
of LSD in Psychiatry: A Systematic Review of Randomized-Controlled
Clinical Trials. Front Psychiatry . 2019;10:943.
doi:10.3389/fpsyt.2019.00943
73. Karst M, Halpern JH, Bernateck M, Passie T. The non-hallucinogen
2-bromo-lysergic acid diethylamide as preventative treatment for cluster
headache: an open, non-randomized case series. Cephalalgia . Sep
2010;30(9):1140-4. doi:10.1177/0333102410363490
74. Andersson M, Persson M, Kjellgren A. Psychoactive substances as a
last resort-a qualitative study of self-treatment of migraine and
cluster headaches. Harm Reduct J . Sep 5 2017;14(1):60.
doi:10.1186/s12954-017-0186-6
75. Fadiman J, Korb S. Might Microdosing Psychedelics Be Safe and
Beneficial? An Initial Exploration. J Psychoactive Drugs . Apr-Jun
2019;51(2):118-122. doi:10.1080/02791072.2019.1593561
76. Sewell RA, Halpern JH, Pope HG, Jr. Response of cluster headache to
psilocybin and LSD. Neurology . Jun 27 2006;66(12):1920-2.
doi:10.1212/01.wnl.0000219761.05466.43
77. Schindler EA, Gottschalk CH, Weil MJ, Shapiro RE, Wright DA, Sewell
RA. Indoleamine Hallucinogens in Cluster Headache: Results of the
Clusterbusters Medication Use Survey. J Psychoactive Drugs .
Nov-Dec 2015;47(5):372-81. doi:10.1080/02791072.2015.1107664
78. Subedi B, Grossberg GT. Phantom limb pain: mechanisms and treatment
approaches. Pain Res Treat . 2011;2011:864605.
doi:10.1155/2011/864605
79. Fanciullacci M, Bene ED, Franchi G, Sicuteri F. Brief report:
Phantom limp pain: sub-hallucinogenic treatment with lysergic acid
diethylamide (LSD-25). Headache . Jul 1977;17(3):118-9.
doi:10.1111/j.1526-4610.1977.hed1703118.x
80. Kuromaru S, Okada S, Hanada M, Kasahara Y, Sakamoto K. The effect of
LSD on the phantom limb phenomenon. J Lancet . Jan
1967;87(1):22-7.
81. Griffiths RR, Johnson MW, Carducci MA, et al. Psilocybin produces
substantial and sustained decreases in depression and anxiety in
patients with life-threatening cancer: A randomized double-blind trial.J Psychopharmacol . Dec 2016;30(12):1181-1197.
doi:10.1177/0269881116675513
82. Schindler EAD, Sewell RA, Gottschalk CH, et al. Exploratory
Controlled Study of the Migraine-Suppressing Effects of Psilocybin.Neurotherapeutics . Jan 2021;18(1):534-543.
doi:10.1007/s13311-020-00962-y
83. Medicine USNLo. Standardized Natural Psilocybin-assisted
Psychotherapy for Tapering of Opioid Medication. 2023.
84. McKenna DJ. Clinical investigations of the therapeutic potential of
ayahuasca: rationale and regulatory challenges. Pharmacol Ther .
May 2004;102(2):111-29. doi:10.1016/j.pharmthera.2004.03.002
85. Bouso CSaJC. Ayahuasca: From the Amazon to the Global Villag.
Transnational Institute; 2015.
86. Jiménez-Garrido DF, Gómez-Sousa M, Ona G, et al. Effects of
ayahuasca on mental health and quality of life in naïve users: A
longitudinal and cross-sectional study combination. Sci Rep . Mar
5 2020;10(1):4075. doi:10.1038/s41598-020-61169-x
87. Barbosa PC, Cazorla IM, Giglio JS, Strassman R. A six-month
prospective evaluation of personality traits, psychiatric symptoms and
quality of life in ayahuasca-naïve subjects. J Psychoactive
Drugs . Sep 2009;41(3):205-12. doi:10.1080/02791072.2009.10400530
88. Goutarel RG, Otto; Sillans, Roger. Pharmacodynamics and Therapeutic
Applications of Iboga and Ibogaine. Psychedelic Monographs and Essays
1993 6 71-1111996.
89. Bagal AA, Hough LB, Nalwalk JW, Glick SD. Modulation of
morphine-induced antinociception by ibogaine and noribogaine.Brain Res . Nov 25 1996;741(1-2):258-62.
doi:10.1016/s0006-8993(96)00938-9
90. Sunder Sharma S, Bhargava HN. Enhancement of morphine
antinociception by ibogaine and noribogaine in morphine-tolerant mice.Pharmacology . Nov 1998;57(5):229-32. doi:10.1159/000028246
91. Weleff J, Akiki TJ, Barnett BS. Bibliometric Analysis of Academic
Journal Articles Reporting Results of Psychedelic Clinical Studies.J Psychoactive Drugs . Sep-Oct 2023;55(4):434-444.
doi:10.1080/02791072.2022.2133757
92. Pisano VD, Putnam NP, Kramer HM, Franciotti KJ, Halpern JH, Holden
SC. The association of psychedelic use and opioid use disorders among
illicit users in the United States. J Psychopharmacol . May
2017;31(5):606-613. doi:10.1177/0269881117691453
93. Argento E, Socias ME, Hayashi K, et al. Psychedelic use is
associated with reduced daily opioid use among people who use illicit
drugs in a Canadian setting. Int J Drug Policy . Feb
2022;100:103518. doi:10.1016/j.drugpo.2021.103518
94. Jones G, Ricard JA, Lipson J, Nock MK. Associations between classic
psychedelics and opioid use disorder in a nationally-representative U.S.
adult sample. Sci Rep . Apr 7 2022;12(1):4099.
doi:10.1038/s41598-022-08085-4
95. Medicine USNLo. Inpatient Buprenorphine Induction With Psilocybin
for Opioid Use Disorder (BIPOD-In). ClinicalTrials.gov2023.
96. Sobell LC, Sobell MB. Timeline Follow-Back. In: Litten RZ, Allen JP,
eds. Measuring Alcohol Consumption: Psychosocial and Biochemical
Methods . Humana Press; 1992:41-72.
97. Medicine USNLo. Adjunctive Effects of Psilocybin and a Formulation
of Buprenorphine. 2021.
98. Medicine USNLo. Psilocybin for Opioid Use Disorder in Patients on
Methadone Maintenance With Ongoing Opioid Use. 2023.
99. Thomas G, Lucas P, Capler NR, Tupper KW, Martin G.
Ayahuasca-assisted therapy for addiction: results from a preliminary
observational study in Canada. Curr Drug Abuse Rev . Mar
2013;6(1):30-42. doi:10.2174/15733998113099990003
100. Hamill J, Hallak J, Dursun SM, Baker G. Ayahuasca: Psychological
and Physiologic Effects, Pharmacology and Potential Uses in Addiction
and Mental Illness. Curr Neuropharmacol . 2019;17(2):108-128.
doi:10.2174/1570159x16666180125095902
101. Fábregas JM, González D, Fondevila S, et al. Assessment of
addiction severity among ritual users of ayahuasca. Drug Alcohol
Depend . Oct 1 2010;111(3):257-61. doi:10.1016/j.drugalcdep.2010.03.024
102. Argento E, Capler R, Thomas G, Lucas P, Tupper KW. Exploring
ayahuasca-assisted therapy for addiction: A qualitative analysis of
preliminary findings among an Indigenous community in Canada. Drug
Alcohol Rev . Nov 2019;38(7):781-789. doi:10.1111/dar.12985
103. Mosca A, Chiappini S, Miuli A, et al. Ibogaine/Noribogaine in the
Treatment of Substance Use Disorders: A Systematic Review of the Current
Literature. Curr Neuropharmacol . 2023;21(11):2178-2194.
doi:10.2174/1570159x21666221017085612
104. Mash DC, Kovera CA, Pablo J, et al. Ibogaine: complex
pharmacokinetics, concerns for safety, and preliminary efficacy
measures. Ann N Y Acad Sci . Sep 2000;914:394-401.
doi:10.1111/j.1749-6632.2000.tb05213.x
105. Knuijver T, Schellekens A, Belgers M, et al. Safety of ibogaine
administration in detoxification of opioid-dependent individuals: a
descriptive open-label observational study. Addiction . Jan
2022;117(1):118-128. doi:10.1111/add.15448
106. Noller GE, Frampton CM, Yazar-Klosinski B. Ibogaine treatment
outcomes for opioid dependence from a twelve-month follow-up
observational study. Am J Drug Alcohol Abuse . 2018;44(1):37-46.
doi:10.1080/00952990.2017.1310218
107. Davis AK, Renn E, Windham-Herman AM, Polanco M, Barsuglia JP. A
Mixed-Method Analysis of Persisting Effects Associated with Positive
Outcomes Following Ibogaine Detoxification. J Psychoactive Drugs .
Sep-Oct 2018;50(4):287-297. doi:10.1080/02791072.2018.1487607
108. Mash DC, Duque L, Page B, Allen-Ferdinand K. Ibogaine
Detoxification Transitions Opioid and Cocaine Abusers Between Dependence
and Abstinence: Clinical Observations and Treatment Outcomes.Front Pharmacol . 2018;9:529. doi:10.3389/fphar.2018.00529
109. Malcolm BJ, Polanco M, Barsuglia JP. Changes in Withdrawal and
Craving Scores in Participants Undergoing Opioid Detoxification
Utilizing Ibogaine. J Psychoactive Drugs . Jul-Aug
2018;50(3):256-265. doi:10.1080/02791072.2018.1447175
110. Medicine USNLo. Preliminary Efficacy and Safety of Ibogaine in the
Treatment of Methadone Detoxification. 2022.
111. Medicine USNLo. A Study of Oral Ibogaine in Opioid Withdrawal.
2022;
112. Glue P, Lockhart M, Lam F, Hung N, Hung CT, Friedhoff L.
Ascending-dose study of noribogaine in healthy volunteers:
pharmacokinetics, pharmacodynamics, safety, and tolerability. J
Clin Pharmacol . Feb 2015;55(2):189-94. doi:10.1002/jcph.404
113. Bornemann J, Close JB, Spriggs MJ, Carhart-Harris R, Roseman L.
Self-Medication for Chronic Pain Using Classic Psychedelics: A
Qualitative Investigation to Inform Future Research. Front
Psychiatry . 2021;12:735427. doi:10.3389/fpsyt.2021.735427
114. Lipton RB, Buse DC, Friedman BW, et al. Characterizing opioid use
in a US population with migraine: Results from the CaMEO study.Neurology . Aug 4 2020;95(5):e457-e468.
doi:10.1212/wnl.0000000000009324
115. Paice JA, Bohlke K, Barton D, et al. Use of Opioids for Adults With
Pain From Cancer or Cancer Treatment: ASCO Guideline. J Clin
Oncol . Feb 1 2023;41(4):914-930. doi:10.1200/jco.22.02198
116. Delorme J, Kerckhove N, Authier N, Pereira B, Bertin C, Chenaf C.
Systematic Review and Meta-Analysis of the Prevalence of Chronic Pain
Among Patients With Opioid Use Disorder and Receiving Opioid
Substitution Therapy. J Pain . Feb 2023;24(2):192-203.
doi:10.1016/j.jpain.2022.08.008
117. Administration USFaD. Psychedelic Drugs: Considerations for
Clinical Investigations. 2023.
118. Johnson M, Richards W, Griffiths R. Human hallucinogen research:
guidelines for safety. J Psychopharmacol . Aug 2008;22(6):603-20.
doi:10.1177/0269881108093587
119. Kiluk BD, Kleykamp BA, Comer SD, et al. Clinical Trial Design
Challenges and Opportunities for Emerging Treatments for Opioid Use
Disorder: A Review. JAMA Psychiatry . Jan 1 2023;80(1):84-92.
doi:10.1001/jamapsychiatry.2022.4020
120. Mücke M, Cuhls H, Radbruch L, et al. Quantitative sensory testing
(QST). English version. Schmerz . Nov 2021;35(Suppl 3):153-160.
Quantitative sensorische Testung (QST). doi:10.1007/s00482-015-0093-2
121. Georgopoulos V, Akin-Akinyosoye K, Zhang W, McWilliams DF, Hendrick
P, Walsh DA. Quantitative sensory testing and predicting outcomes for
musculoskeletal pain, disability, and negative affect: a systematic
review and meta-analysis. Pain . Sep 2019;160(9):1920-1932.
doi:10.1097/j.pain.0000000000001590
122. Crombez G, Van Ryckeghem DML, Eccleston C, Van Damme S. Attentional
bias to pain-related information: a meta-analysis. Pain . Apr
2013;154(4):497-510. doi:10.1016/j.pain.2012.11.013
123. Kiluk BD, Yip SW, DeVito EE, Carroll KM, Sofuoglu M. Anhedonia as a
key clinical feature in the maintenance and treatment of opioid use
disorder. Clin Psychol Sci . Nov 2019;7(6):1190-1206.
doi:10.1177/2167702619855659
124. Saraiya TC, Jarnecke AM, Jones J, Brown DG, Brady KT, Back SE.
Laboratory-induced stress and craving predict opioid use during
follow-up among individuals with prescription opioid use disorder.Drug Alcohol Depend . Aug 1 2021;225:108755.
doi:10.1016/j.drugalcdep.2021.108755
125. Glue P, Cape G, Tunnicliff D, et al. Ascending Single-Dose,
Double-Blind, Placebo-Controlled Safety Study of Noribogaine in
Opioid-Dependent Patients. Clin Pharmacol Drug Dev . Nov
2016;5(6):460-468. doi:10.1002/cpdd.254
126. Olson DE. The Subjective Effects of Psychedelics May Not Be
Necessary for Their Enduring Therapeutic Effects. ACS Pharmacol
Transl Sci . Apr 9 2021;4(2):563-567. doi:10.1021/acsptsci.0c00192
127. Yaden DB, Griffiths RR. The Subjective Effects of Psychedelics Are
Necessary for Their Enduring Therapeutic Effects. ACS Pharmacol
Transl Sci . Apr 9 2021;4(2):568-572. doi:10.1021/acsptsci.0c00194
128. Roseman L, Nutt DJ, Carhart-Harris RL. Quality of Acute Psychedelic
Experience Predicts Therapeutic Efficacy of Psilocybin for
Treatment-Resistant Depression. Front Pharmacol . 2017;8:974.
doi:10.3389/fphar.2017.00974
129. Schindler EAD. Psychedelics in the Treatment of Headache and
Chronic Pain Disorders. Curr Top Behav Neurosci . 2022;56:261-285.
doi:10.1007/7854_2022_365
130. Johnson MW, Garcia-Romeu A, Cosimano MP, Griffiths RR. Pilot study
of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction.J Psychopharmacol . Nov 2014;28(11):983-92.
doi:10.1177/0269881114548296
131. Hoffman BM, Papas RK, Chatkoff DK, Kerns RD. Meta-analysis of
psychological interventions for chronic low back pain. Health
Psychol . Jan 2007;26(1):1-9. doi:10.1037/0278-6133.26.1.1
132. Dutra L, Stathopoulou G, Basden SL, Leyro TM, Powers MB, Otto MW. A
meta-analytic review of psychosocial interventions for substance use
disorders. Am J Psychiatry . Feb 2008;165(2):179-87.
doi:10.1176/appi.ajp.2007.06111851
133. Brennan W, Belser AB. Models of Psychedelic-Assisted Psychotherapy:
A Contemporary Assessment and an Introduction to EMBARK, a
Transdiagnostic, Trans-Drug Model. Front Psychol . 2022;13:866018.
doi:10.3389/fpsyg.2022.866018
134. Cavarra M, Falzone A, Ramaekers JG, Kuypers KPC, Mento C.
Psychedelic-Assisted Psychotherapy-A Systematic Review of Associated
Psychological Interventions. Front Psychol . 2022;13:887255.
doi:10.3389/fpsyg.2022.887255
135. Yaden DB, Berghella AP, Regier PS, Garcia-Romeu A, Johnson MW,
Hendricks PS. Classic psychedelics in the treatment of substance use
disorder: Potential synergies with twelve-step programs. Int J
Drug Policy . Dec 2021;98:103380. doi:10.1016/j.drugpo.2021.103380
136. Pronovost-Morgan C, Hartogsohn I, Ramaekers JG. Harnessing placebo:
Lessons from psychedelic science. J Psychopharmacol . Sep
2023;37(9):866-875. doi:10.1177/02698811231182602
137. Henderson LA, Di Pietro F, Youssef AM, et al. Effect of Expectation
on Pain Processing: A Psychophysics and Functional MRI Analysis.Front Neurosci . 2020;14:6. doi:10.3389/fnins.2020.00006
138. Hovmand OR, Poulsen ED, Arnfred S, Storebø OJ. Risk of bias in
randomized clinical trials on psychedelic medicine: A systematic review.J Psychopharmacol . Jul 2023;37(7):649-659.
doi:10.1177/02698811231180276
139. Szigeti B, Nutt D, Carhart-Harris R, Erritzoe D. The difference
between ’placebo group’ and ’placebo control’: a case study in
psychedelic microdosing. Sci Rep . Jul 26 2023;13(1):12107.
doi:10.1038/s41598-023-34938-7
140. Gukasyan N, Nayak SM. Psychedelics, placebo effects, and set and
setting: Insights from common factors theory of psychotherapy.Transcult Psychiatry . Oct 2022;59(5):652-664.
doi:10.1177/1363461520983684
141. Gukasyan N, Davis AK, Barrett FS, et al. Efficacy and safety of
psilocybin-assisted treatment for major depressive disorder: Prospective
12-month follow-up. J Psychopharmacol . Feb 2022;36(2):151-158.
doi:10.1177/02698811211073759
142. Henningfield JE, Ashworth J, Heal DJ, Smith SL. Psychedelic drug
abuse potential assessment for new drug applications and controlled
substance scheduling: A United States perspective. J
Psychopharmacol . Jan 2023;37(1):33-44. doi:10.1177/02698811221140004
143. Breeksema JJ, Kuin BW, Kamphuis J, van den Brink W, Vermetten E,
Schoevers RA. Adverse events in clinical treatments with serotonergic
psychedelics and MDMA: A mixed-methods systematic review. J
Psychopharmacol . Oct 2022;36(10):1100-1117.
doi:10.1177/02698811221116926
144. Johnston CB, Mangini M, Grob C, Anderson B. The Safety and Efficacy
of Psychedelic-Assisted Therapies for Older Adults: Knowns and Unknowns.Am J Geriatr Psychiatry . Jan 2023;31(1):44-53.
doi:10.1016/j.jagp.2022.08.007
145. Goodwin GM, Aaronson ST, Alvarez O, et al. Single-Dose Psilocybin
for a Treatment-Resistant Episode of Major Depression. N Engl J
Med . Nov 3 2022;387(18):1637-1648. doi:10.1056/NEJMoa2206443
146. Halpern JH, Pope HG, Jr. Hallucinogen persisting perception
disorder: what do we know after 50 years? Drug Alcohol Depend .
Mar 1 2003;69(2):109-19. doi:10.1016/s0376-8716(02)00306-x
147. Rocha JM, Reis JAS, Bouso JC, Hallak JEC, Dos Santos RG.
Identifying setting factors associated with improved ibogaine safety: a
systematic review of clinical studies. Eur Arch Psychiatry Clin
Neurosci . Oct 2023;273(7):1527-1542. doi:10.1007/s00406-023-01590-1
148. McIntyre RS. Serotonin 5-HT(2B) receptor agonism and valvular heart
disease: implications for the development of psilocybin and related
agents. Expert Opin Drug Saf . Jul-Dec 2023;22(10):881-883.
doi:10.1080/14740338.2023.2248883